NCT07163156Enrolling by invitation
Prolactin, Inflammation, and Parkinson's Severity
The Relationship of Prolactin and Inflammatory Markers With Parkinson's Disease Severity: Clinical and Biochemical Evaluation
Source: ClinicalTrials.gov · Last updated 9 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 23 Aug 2025
- Start date
- 14 Aug 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- Çanakkale Onsekiz Mart University
- Diseases
- Parkinson disease
- NCT number
- NCT07163156
What you commit to
- Study type: Observational
- Planned participants: 300
- From 14 Aug 2025 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications known to alter prolactin secretion (e.g., antipsychotics, dopamine antagonists, estrogen therapy)
Other illness
- Patients with secondary or atypical parkinsonism (e.g., drug-induced, vascular, atypical parkinsonian syndromes)
- Known endocrine disorders affecting prolactin levels (e.g., prolactinoma, pituitary adenoma, hypothyroidism)
- History of other neurodegenerative diseases (e.g., Alzheimer's, Huntington's)
- Presence of active infection, chronic inflammatory disease, or malignancy
- Severe renal, hepatic, or cardiac failure
Other
- Premenopausal female patients
- Inability to provide informed consent
Who the study is looking for
- Age ≥ 18 years
- Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
- Both male and postmenopausal female patients
- Patients able to provide informed consent
- Clinically stable enough to undergo blood and saliva sampling, as well as neurological assessment
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Çanakkale Onsekiz Mart University Coordinator of this site? Confirm its status | Çanakkale | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.